A M Brewster

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 118:5637-43. 2012
  2. ncbi Tumor-suppressor activity of RRIG1 in breast cancer
    Guihong Zhang
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 11:32. 2011
  3. ncbi Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Oncologist 16:935-41. 2011
  4. ncbi Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    Abenaa M Brewster
    Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:1179-83. 2008
  5. ncbi Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival
    A M Brewster
    Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer Prev Res (Phila) 4:1609-16. 2011
  6. ncbi Relationship between epidemiologic risk factors and breast cancer recurrence
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:4438-44. 2007
  7. ncbi The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers
    A M Brewster
    The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 130:897-904. 2011
  8. ncbi Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer
    A M Brewster
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 95:73-80. 2006
  9. ncbi Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 103:1147-53. 2005
  10. ncbi Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research
    Abenaa M Brewster
    The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 3:1044-8. 2010

Research Grants

  1. Insulin Resistance and Breast Cancer Outcome
    Abenaa Brewster; Fiscal Year: 2007

Detail Information

Publications17

  1. ncbi Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 118:5637-43. 2012
    ..The objective of this study was to evaluate the benefits of CPM using a propensity scoring approach that reduces selection bias from the nonrandom assignment of patients in observational studies...
  2. ncbi Tumor-suppressor activity of RRIG1 in breast cancer
    Guihong Zhang
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 11:32. 2011
    ..The aim of this study was to determine whether RRIG1 plays a role in breast cancer, such as in the suppression of breast cancer cell growth and invasion...
  3. ncbi Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Oncologist 16:935-41. 2011
    ..Gaps in knowledge about the clinical value of CPM, including patient- and physician-related psychosocial factors that influence the decision-making process of CPM among women with sporadic breast cancer, are highlighted...
  4. ncbi Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    Abenaa M Brewster
    Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:1179-83. 2008
    ..Breast cancer patients have a substantial residual risk of recurrence, and selected tumor characteristics are associated with late recurrences...
  5. ncbi Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival
    A M Brewster
    Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer Prev Res (Phila) 4:1609-16. 2011
    ..Measurement of tumor genotype has the potential to improve discrimination between indolent and aggressive screen-detected tumors and aids patient and physician decision making about use of surgical and adjuvant treatments...
  6. ncbi Relationship between epidemiologic risk factors and breast cancer recurrence
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:4438-44. 2007
    ..We evaluated the effect of epidemiologic breast cancer risk factors on recurrence in women with early-stage disease...
  7. ncbi The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers
    A M Brewster
    The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 130:897-904. 2011
    ..Further investigation is needed into other factors that contribute to patient disparities in the receipt of chemotherapy in major academic centers...
  8. ncbi Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer
    A M Brewster
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 95:73-80. 2006
    ..Without imputation methods for handling missing data, a statistically significant association was observed between the genotypes and breast cancer, illustrating the potential for bias in studies that inadequately handle missing data...
  9. ncbi Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 103:1147-53. 2005
    ..Baseline incidence also was examined for adverse health events in this community-based cohort compared with participants in the Breast Cancer Prevention Trial...
  10. ncbi Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research
    Abenaa M Brewster
    The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 3:1044-8. 2010
    ....
  11. ncbi Ductal carcinoma in situ: state of the science and roadmap to advance the field
    Henry M Kuerer
    The University of Texas M D Anderson Cancer Center, DCIS Discovery Program and Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 27:279-88. 2009
    ..Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field...
  12. ncbi XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Epidemiol Biomarkers Prev 13:1271-5. 2004
    ..To test this hypothesis, a cohort study was conducted to examine the association between XPD Lys751Gln polymorphism and risk of a second primary cancer in individuals with NMSC...
  13. ncbi Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4072-7. 2008
    ..To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer...
  14. ncbi The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger
    Chan H Han
    Department of Epidemiology, Unit 1365, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res Treat 122:243-9. 2010
    ..In conclusion, the PIN1 polymorphisms may contribute to the etiology of sporadic breast cancer in non-Hispanic white women 55 years and younger. Further validation in large population-based studies is needed...
  15. ncbi Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:1974-8. 2007
    ....
  16. ncbi Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years
    Jiachun Lu
    Department of Epidemiology, Unit 1365, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Breast Cancer Res Treat 110:357-66. 2008
    ..Larger association studies and related functional studies are warranted to confirm these findings...
  17. ncbi Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7909-16. 2008
    ..We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)...

Research Grants1

  1. Insulin Resistance and Breast Cancer Outcome
    Abenaa Brewster; Fiscal Year: 2007
    ..This information will be useful in identifying women who may benefit from interventions to decrease insulin resistance as part of their breast cancer care. ..